AstraZeneca has teamed up with RNA vaccine and therapeutic developer VaxEquity, investing US$195m in milestone payments alone.

The EIF has invested €25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.

The largest biotech event organised by a national bioindustry association (AseBio) in Europe and one of the biggest in the world will take place from 27 September to 1 October. To be held in Pamplona-Iruña, the capital of the region of Navarra, and a scientific cluster for biotechnology, BioSpain will feature
a combination of on-site networking opportunities and site visits, an online trade show, presentations,
and panels that will be accessible simultaneously on-site and online.

By applying the expertise, best practice, and emerging technologies of the logistics industry,  biotech not only prevents the missteps that can destroy its products, it can also capitalise on opportunities to get to new markets faster, safer and more cost effectively.

The COVID-19 pandemic has demonstrated how vulnerable human beings and societies are to a new infectious disease, and how important the life science industry is to come up with diagnostic and therapeutic solutions.

Boehringer Ingelheim has acquired Texan biotech Abexxa Biologics Inc., further expanding its cancer immunotherapy pipeline.

Following the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest €307m in the company’s producion site near Dublin.

Bayer AG has joined forces with young Danish biotech Gubra ApS in a research collaboration and license agreement for the development of peptide therapeutics to treat cardiorenal diseases.

The Novo Nordisk Foundation is investing US$47.5m into a research collaboration with the Broad Institute of MIT and Harvard, intending to dive into the disease mechanisms of diabetes and obesity.

UK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to  a current aggregate total of US $125m.